Betaine and Homocysteine: Why Lowering It May Not Help Your Heart

By Erin Rose · Updated July 19, 2026 · Methodology

Educational overview — not medical advice. Homocysteine management, and any decision to supplement at 6g/day, should involve a clinician, especially if you have or are managing elevated cholesterol. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

The reliably-replicated effect, precisely

Olthof et al. 2003 randomized 76 healthy men and women (4 groups of 19) to 1.5g, 3g, or 6g/day betaine vs placebo for 6 weeks: fasting homocysteine fell 12% (1.5g), 15% (3g), and 20% (6g) vs placebo, and post-methionine-loading homocysteine rise was reduced 23-40% across the dose groups — a clean, statistically significant, dose-dependent result with the primary endpoint clearly met. Schwab et al. 2006 pushed the timeline further: a randomized double-blind crossover in 10 healthy adults found single 3g and 6g doses significantly lowered plasma homocysteine within just 2 hours (p=0.019 and p<0.001 respectively), in a clear linear dose-response (p=0.006) — while a single 1g dose did not move homocysteine at all. Betaine anhydrous is even an FDA-approved prescription drug (Cystadane) for homocystinuria, a rare genetic disorder of homocysteine metabolism, typically dosed well above supplement range under medical supervision — real clinical confirmation that betaine reliably affects this pathway, not a reason a healthy person should self-dose at drug-level amounts.

Caveat one: homocysteine is a surrogate marker, not a heart-disease outcome

This is the single most important sentence on this page: lowering homocysteine has not been shown to reduce cardiovascular events. No outcome trial in this evidence base — or in the broader homocysteine-lowering literature generally — demonstrates that betaine supplementation reduces heart attacks, strokes, or cardiovascular mortality. Homocysteine is an easy biomarker to measure and a genuinely interesting one biologically, but a biomarker moving in the expected direction is not the same as a proven clinical benefit. This site never states or implies that betaine "protects your heart" or reduces cardiovascular risk — that would be a bigger claim than the evidence supports, no matter how consistent the homocysteine-lowering data is.

Caveat two: the LDL/cholesterol trade-off at the effective dose

Olthof et al. 2005, a combined analysis of three betaine RCTs (n=151) at 1.5g, 3g, and 6g/day over 6 weeks, found 6g/day betaine raised LDL cholesterol by 0.36 mmol/L (95% CI 0.25–0.46), triglycerides by 0.14 mmol/L (0.04–0.23), and the total:HDL ratio by 0.23 (0.14–0.32) — HDL itself was unaffected. Lower doses (1.5g, 3g) showed non-significant lipid increases. The authors' own conclusion: betaine "increased blood LDL cholesterol and triacylglycerol concentrations in healthy humans." Independently, Schwab et al. 2002 — a 12-week RCT in 42 obese adults at 6g/day — found total and LDL cholesterol significantly higher in the betaine group (p<0.05), even though the trial's primary body-composition endpoint (weight, resting energy expenditure, fat mass) showed no betaine advantage over diet alone. Two independent trials, the same lipid direction, at the same dose that lowers homocysteine most effectively. This is the trade-off to weigh, especially if you're already managing elevated cholesterol — talk to a clinician before supplementing at 6g/day for this purpose.

Not uniformly robust: the duration caveat

The homocysteine effect is well-replicated specifically as a short-term, 3-6g/day finding — it is not automatically true at every dose sustained for any length of time. Schwab et al. 2011, a 6-month RCT in 63 healthy young adults at 4g/day, found plasma homocysteine did not change significantly in either group, and the authors described the lowering effect as "weak" in their own words. Interestingly, this same 6-month trial found LDL/total cholesterol showed a significant time-by-group interaction but no clear between-group difference, and PAI-1 (a clotting-related marker) rose in the betaine group (p=0.028) while falling in controls (p=0.006) — a mixed, honestly-reported result that underscores why "3-6g/day, short-term" is the well-supported claim, not "any dose, indefinitely."

What this evidence does not claim

To be explicit: this page does not claim betaine treats, prevents, or reduces risk of any cardiovascular disease. It does not claim the homocysteine-lowering effect is free of trade-offs. And it does not claim the effect is uniformly robust regardless of dose or duration — Schwab 2011 shows plainly that it isn't. What the evidence does support: betaine reliably and measurably lowers homocysteine at 3-6g/day in the short term, a genuine, well-replicated biochemical effect, reported here alongside both of its real caveats rather than in isolation.

Compare Betaine (TMG) Products

If you're ready to buy, here's how the betaine (TMG) products we track and verify compare on cost per gram.

Frequently asked questions

Related

• Betaine (TMG): homocysteine and pre-workout, honestly explained
• Betaine dosage guide — the full dose spine
• Best betaine — ranked by cost per gram
• Does betaine work for strength?
• Methylfolate — remethylates homocysteine via a separate pathway
• Vitamin B12 — the third leg of the homocysteine-remethylation triad

Sources